Nexalin Technology, Inc. Warrant
NXLIW
About: Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.
Employees: 7
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
52.27% more ownership
Funds ownership: 7.3% [Q1] → 59.57% (+52.27%) [Q2]
17% more funds holding
Funds holding: 6 [Q1] → 7 (+1) [Q2]
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
69% less capital invested
Capital invested by funds: $195K [Q1] → $61.4K (-$134K) [Q2]
Financial journalist opinion
We haven’t received any recent news articles for NXLIW